Neuberger Berman Group LLC Has $74.41 Million Stock Holdings in DexCom, Inc. $DXCM

Neuberger Berman Group LLC boosted its position in DexCom, Inc. (NASDAQ:DXCM) by 41.6% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 1,105,730 shares of the medical device company’s stock after acquiring an additional 324,849 shares during the quarter. Neuberger Berman Group LLC’s holdings in DexCom were worth $74,405,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. Norges Bank bought a new position in DexCom in the second quarter worth approximately $453,279,000. Groupama Asset Managment grew its stake in DexCom by 79,043.1% in the second quarter. Groupama Asset Managment now owns 4,016,513 shares of the medical device company’s stock valued at $350,601,000 after acquiring an additional 4,011,438 shares during the period. Massachusetts Financial Services Co. MA increased its holdings in shares of DexCom by 106.8% during the second quarter. Massachusetts Financial Services Co. MA now owns 6,605,687 shares of the medical device company’s stock valued at $576,610,000 after acquiring an additional 3,410,858 shares in the last quarter. Marshall Wace LLP increased its holdings in shares of DexCom by 260.7% during the second quarter. Marshall Wace LLP now owns 3,822,085 shares of the medical device company’s stock valued at $333,630,000 after acquiring an additional 2,762,504 shares in the last quarter. Finally, Federated Hermes Inc. raised its position in shares of DexCom by 82.1% during the second quarter. Federated Hermes Inc. now owns 3,633,139 shares of the medical device company’s stock worth $317,137,000 after purchasing an additional 1,638,407 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Stock Down 3.7%

DXCM stock opened at $68.10 on Friday. The firm has a market capitalization of $26.21 billion, a PE ratio of 32.43, a P/E/G ratio of 1.37 and a beta of 1.48. The company has a quick ratio of 1.59, a current ratio of 1.88 and a debt-to-equity ratio of 0.45. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $89.98. The stock’s 50 day moving average is $70.69 and its 200-day moving average is $68.93.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, February 12th. The medical device company reported $0.68 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.03. The business had revenue of $1.26 billion during the quarter, compared to the consensus estimate of $1.25 billion. DexCom had a return on equity of 32.12% and a net margin of 17.94%.DexCom’s revenue was up 13.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.45 earnings per share. Sell-side analysts expect that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on DXCM. Leerink Partners reiterated an “outperform” rating and issued a $92.00 target price on shares of DexCom in a report on Tuesday, December 16th. Mizuho boosted their price target on shares of DexCom from $78.00 to $90.00 and gave the company an “outperform” rating in a research note on Friday, February 13th. Wells Fargo & Company lowered their price objective on shares of DexCom from $93.00 to $85.00 and set an “overweight” rating on the stock in a report on Friday, February 13th. Piper Sandler reaffirmed an “overweight” rating on shares of DexCom in a research note on Thursday, February 5th. Finally, Truist Financial reiterated a “buy” rating and set a $80.00 price objective (down from $82.00) on shares of DexCom in a report on Tuesday, February 17th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $85.18.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.